Carpenter joined the military after 9/11. He was on active duty in Iraq and in the Middle East and returned home after ...

Achieving goals one step at a time. Jessica Bowman takes you inside a CNOS physical therapy treatment as one therapist works to help a local patient to walk again.

The company’s lead investigational therapy, tanruprubart ... The firm is optimistic about the potential approval of ANX005 for Guillain-Barré Syndrome (GBS) and the safety and activity of ANX1502 in ...

The company’s lead investigational therapy, tanruprubart ... the potential approval of ANX005 for Guillain-Barré Syndrome (GBS) and the safety and activity of ANX1502 in Cold Agglutinin ...

to stop C1q activity in the peripheral and central nervous systems; the clinical and regulatory status of ANX005; and the potential therapeutic benefit of ANX005; the potential benefits from treatment ...

First Oral Presentation by the International Guillain-Barré Syndrome Outcomes ... the potential benefits from treatment with anti-C1q therapy; and continuing advancement of the company’s ...

Annexon’s lead investigational therapy, tanruprubart, is a first-of-its kind selective, targeted and rapid-acting agent designed to reduce inflammation and nerve damage by stopping C1q activity ...